PharmaEssentia Included in FTSE Russell Indices

TAIPEI–(BUSINESS WIRE)–PharmaEssentia Corporation, (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the company is included in the FTSE Global Equity Index Series, FTSE All-World Index, FTSE global All-Cap and total-Cap Indices, and the FTSE Global Mid Cap Index. These inclusions became effective after close of business on Friday, September 15, 2023.

Used extensively by institutional and retail investors globally, FTSE Russell is a global index leader and a wholly owned subsidiary of the London Stock Exchange Group.

About PharmaEssentia

PharmaEssentia (TPEx: 6446), headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.

For more information on PharmaEssentia Corporation, visit our website.

 

Contacts

Media Contact:
Rachel Lipsitz, rachel_lipsitz@pharmaessentia.com